Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why? -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Shaffer who wrote (300)	11/19/1997 1:05:00 PM
From: Douglas	Read Replies (2) \| Respond to of 455

A special meeting of the stockholders of Procept was held on September 29, 1997. Item 2 of the purposes was approved: 2. To approve the issuance of up to a maximum of 200 units to investors in a private placement, with each unit consisting of 1,000 shares of Series B Convertible Preferred Stock and warrants to purchase 333,333 shares of common stock. Daniel, did you notice the Reuters Health News Release "Effective HIV Vaccine May Take Decades to Develop, dated 18 November 1997, 23:00 GMT" The release said " Dr. David Baltimore believes it is extremely unlikely that a vaccine to prevent HIV infection will be developed, and a vaccine to protect HIV-positive individuals against progression to AIDS could be decades away.. Dr. Baltimore, chairman of the AIDS Vaccine Research Committee at the US office of AIDS Research, was speaking over the weekend at a 2-day symposium in Singapore to celebrate the 10th anniversary of the Institute of Molecular and Cell Biology there." My view: the cost of treatment medication (triple cocktail) is too high, vaccines will probably never happen (liability issues), possibility of being cured is becoming remote (virus remains in the blood), more emphasis on prevention is forthcoming. Topical microbicides are going to receive more publicity. Let's hope that Procept leads the charge!